JP2020515256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515256A5 JP2020515256A5 JP2019553013A JP2019553013A JP2020515256A5 JP 2020515256 A5 JP2020515256 A5 JP 2020515256A5 JP 2019553013 A JP2019553013 A JP 2019553013A JP 2019553013 A JP2019553013 A JP 2019553013A JP 2020515256 A5 JP2020515256 A5 JP 2020515256A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen
- mutant
- binding
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 102000005962 receptors Human genes 0.000 claims description 62
- 108020003175 receptors Proteins 0.000 claims description 62
- 230000003834 intracellular effect Effects 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000004873 anchoring Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 8
- 108010087819 Fc receptors Proteins 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 4
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023050868A JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163090 | 2017-03-27 | ||
| EP17163090.8 | 2017-03-27 | ||
| PCT/EP2018/057566 WO2018177966A1 (en) | 2017-03-27 | 2018-03-26 | Improved antigen binding receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050868A Division JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515256A JP2020515256A (ja) | 2020-05-28 |
| JP2020515256A5 true JP2020515256A5 (enExample) | 2021-04-30 |
Family
ID=58428198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553013A Pending JP2020515256A (ja) | 2017-03-27 | 2018-03-26 | 改良された抗原結合受容体 |
| JP2023050868A Active JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050868A Active JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11679127B2 (enExample) |
| EP (1) | EP3600407B1 (enExample) |
| JP (2) | JP2020515256A (enExample) |
| KR (1) | KR102712254B1 (enExample) |
| CN (1) | CN110662560B (enExample) |
| AU (1) | AU2018241624B2 (enExample) |
| BR (1) | BR112019020168A2 (enExample) |
| CA (1) | CA3056837A1 (enExample) |
| CL (1) | CL2019002717A1 (enExample) |
| CR (1) | CR20190440A (enExample) |
| ES (1) | ES3010117T3 (enExample) |
| IL (1) | IL269531B2 (enExample) |
| MA (2) | MA49270A (enExample) |
| MX (1) | MX2019011526A (enExample) |
| MY (1) | MY205503A (enExample) |
| PE (1) | PE20200152A1 (enExample) |
| SG (1) | SG11201908796XA (enExample) |
| TW (1) | TWI890655B (enExample) |
| UA (1) | UA128717C2 (enExample) |
| WO (1) | WO2018177966A1 (enExample) |
| ZA (1) | ZA201906358B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| ES3000558T3 (en) | 2016-08-10 | 2025-02-28 | Univ Ajou Ind Academic Coop Found | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| US20200223925A1 (en) * | 2018-12-21 | 2020-07-16 | Hoffmann-La Roche Inc. | Tumor-targeted superagonistic cd28 antigen binding molecules |
| WO2020127618A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
| US20220152108A1 (en) * | 2019-03-18 | 2022-05-19 | Svenska Vaccinfabriken Produktion Ab | Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor |
| CN114007643A (zh) | 2019-04-19 | 2022-02-01 | 中外制药株式会社 | 识别抗体改变部位的嵌合受体 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| JP2023531067A (ja) * | 2020-06-25 | 2023-07-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子 |
| US20230322898A1 (en) | 2020-07-31 | 2023-10-12 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising cell expressing chimeric receptor |
| WO2022029051A1 (en) * | 2020-08-03 | 2022-02-10 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| AU2021329375A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| CN111995689B (zh) * | 2020-08-27 | 2023-05-05 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| EP4237449A1 (en) * | 2020-10-28 | 2023-09-06 | F. Hoffmann-La Roche AG | Improved antigen binding receptors |
| CN117730102A (zh) | 2021-07-22 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 异二聚体Fc结构域抗体 |
| AU2022397540A1 (en) * | 2021-11-25 | 2024-05-16 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| CN116162168A (zh) * | 2021-11-25 | 2023-05-26 | 信达细胞制药(苏州)有限公司 | 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用 |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| JP2025512797A (ja) * | 2022-03-25 | 2025-04-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 改善されたキメラ受容体 |
| WO2023242343A1 (en) | 2022-06-15 | 2023-12-21 | Immunoscape Pte. Ltd. | Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof |
| AR130387A1 (es) | 2022-09-08 | 2024-12-04 | Hoffmann La Roche | Receptores de linfocitos t recombinantes |
| EP4590322A1 (en) * | 2022-09-20 | 2025-07-30 | Dana-Farber Cancer Institute, Inc. | Reversible control of chimeric antigen receptor t cells |
| CN120548192A (zh) | 2023-01-20 | 2025-08-26 | 豪夫迈·罗氏有限公司 | 免疫缀合物 |
| WO2024251547A1 (en) | 2023-06-06 | 2024-12-12 | F. Hoffmann-La Roche Ag | Switch receptors |
| WO2024251132A1 (zh) * | 2023-06-06 | 2024-12-12 | 信达细胞制药(苏州)有限公司 | 一种包含bcma pg car-t细胞制剂和pg抗体制剂的药物组合制剂及其用途 |
| WO2025146286A1 (en) | 2024-01-04 | 2025-07-10 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025181329A1 (en) | 2024-03-01 | 2025-09-04 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025233304A1 (en) | 2024-05-08 | 2025-11-13 | F. Hoffmann-La Roche Ag | Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides |
| CN119074926B (zh) * | 2024-08-29 | 2025-11-25 | 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) | 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| DE602005011617D1 (de) | 2004-05-19 | 2009-01-22 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP2402374A1 (en) | 2005-02-07 | 2012-01-04 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| JP2016528167A (ja) | 2013-04-29 | 2016-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトＦｃＲｎ結合改変抗体及び使用方法 |
| KR102266819B1 (ko) * | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| US20170151283A1 (en) * | 2014-05-23 | 2017-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
| MX2017003062A (es) * | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Receptores quimericos y usos de los mismos en terapia inmune. |
| KR102558502B1 (ko) | 2014-12-05 | 2023-07-20 | 시티 오브 호프 | Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포 |
| CN114891102A (zh) | 2015-10-29 | 2022-08-12 | 豪夫迈·罗氏有限公司 | 抗变体Fc区抗体及使用方法 |
| SG11201908784TA (en) | 2017-03-27 | 2019-10-30 | Hoffmann La Roche | Improved antigen binding receptor formats |
-
2018
- 2018-03-26 AU AU2018241624A patent/AU2018241624B2/en active Active
- 2018-03-26 WO PCT/EP2018/057566 patent/WO2018177966A1/en not_active Ceased
- 2018-03-26 UA UAA201910455A patent/UA128717C2/uk unknown
- 2018-03-26 MA MA049270A patent/MA49270A/fr unknown
- 2018-03-26 MY MYPI2019005602A patent/MY205503A/en unknown
- 2018-03-26 BR BR112019020168-8A patent/BR112019020168A2/pt unknown
- 2018-03-26 CN CN201880034376.0A patent/CN110662560B/zh active Active
- 2018-03-26 CR CR20190440A patent/CR20190440A/es unknown
- 2018-03-26 TW TW107110249A patent/TWI890655B/zh active
- 2018-03-26 KR KR1020197031539A patent/KR102712254B1/ko active Active
- 2018-03-26 MX MX2019011526A patent/MX2019011526A/es unknown
- 2018-03-26 IL IL269531A patent/IL269531B2/en unknown
- 2018-03-26 MA MA049990A patent/MA49990A/fr unknown
- 2018-03-26 EP EP18712231.2A patent/EP3600407B1/en active Active
- 2018-03-26 SG SG11201908796X patent/SG11201908796XA/en unknown
- 2018-03-26 JP JP2019553013A patent/JP2020515256A/ja active Pending
- 2018-03-26 ES ES18712231T patent/ES3010117T3/es active Active
- 2018-03-26 CA CA3056837A patent/CA3056837A1/en active Pending
- 2018-03-26 PE PE2019001946A patent/PE20200152A1/es unknown
-
2019
- 2019-09-19 US US16/576,546 patent/US11679127B2/en active Active
- 2019-09-24 CL CL2019002717A patent/CL2019002717A1/es unknown
- 2019-09-26 ZA ZA2019/06358A patent/ZA201906358B/en unknown
-
2023
- 2023-03-28 JP JP2023050868A patent/JP7642010B2/ja active Active
- 2023-05-04 US US18/312,339 patent/US12291561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515256A5 (enExample) | ||
| US11208459B2 (en) | Constructs having a SIRP-alpha domain or variant thereof | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| CN108699157B (zh) | Psma结合抗体及其用途 | |
| JP2020514375A5 (enExample) | ||
| JP2018504092A5 (enExample) | ||
| CN118496374A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| CN111712518A (zh) | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 | |
| WO2021207242A2 (en) | Anti-mesothelin antigen-binding molecules and uses thereof | |
| US20230355795A1 (en) | Immune antigen specific il-18 immunocytokines and uses thereof | |
| US20250163157A1 (en) | Bispecific antibodies against cd277 and a tumor-antigen | |
| CA3224147A1 (en) | Antibody conjugates and manufacture thereof | |
| CN117425484A (zh) | 多功能免疫细胞疗法 | |
| WO2022057875A1 (zh) | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 | |
| WO2023143535A1 (zh) | 一种靶向il-18bp的抗体及其应用 | |
| JP2025170264A (ja) | 抗ｂｃｍａ剤のための投与レジメン | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| TW202241967A (zh) | 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物 | |
| CA3163035A1 (en) | Chemically induced association and dissociation of therapeutic fc compositions and chemically induced dimerization of t cell engager with human serum albumin | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| EP4320156A1 (en) | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains | |
| RU2019133202A (ru) | Улучшенные антигенсвязывающие рецепторы | |
| US20250186597A1 (en) | Targeted immune activation with il-18 immunocytokines | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof |